Clinical trials: Aggression, open to volunteers
Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (<12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan…
- Conditions
- Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor, Gastrointestinal Stromal Tumors, Ovarian Germ Cell Tumor
- Trial name
- SUR-CAN (NCT05500391)
- Testing
- Oncological Follow-up
- Where
- 3 sites in France
- Volunteers
- 88 people
- Sponsor
- Centre Oscar Lambret
Bullying, Teen Dating Violence
Using an Innovative Implementation Strategy to Increase the Translation of Effective Youth Violence Prevention Programs in Schools
The purpose of this study is to Adapt the existing iCHAMPSS's tools to support school policies related to the adoption, implementation, and maintenance of effective youth bullying and dating violence prevention programs…
- Trial name
- NCT07223957
- Testing
- iCHAMPS-YVP
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- The University of Texas Health Science Center, Houston
Non-Hodgkin Lymphoma, B-cell
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell…
- Trial name
- JASPIS-01 (NCT06534437)
- Testing
- MEN1703, Glofitamab
- Where
- 35 sites in France, Poland and 2 more
- Volunteers
- 178 people
- Sponsor
- Ryvu Therapeutics SA
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and…
- Conditions
- High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06649812
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 114 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, B-cell Lymphomas
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
The goal of this clinical trial is to assess the clinical efficacy of bridging therapy with glofitamab/gemcitabine/oxaliplatin (Glofit-GemOx) followed by lisocabtagene maraleucel (liso-cel) in relapsed/refractory large B-cell…
- Conditions
- Lymphoma, B-cell Lymphomas, Relapsed/Refractory Large B-cell Lymphoma, Large B-cell Lymphoma
- Trial name
- GLORY (NCT07711483)
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Massachusetts General Hospital
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cerebral spinal fluid/CSF ctDNA but test negative for CNS involvement…
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Stage III High Grade B-Cell Lymphoma, Stage IV High Grade B-Cell Lymphoma
- Trial name
- NCT06736613
- Testing
- Cerebral Spinal Fluid ctDNA
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Schizophrenia Disorder, Schizoaffecitve Disorder
A Virtual Reality Mindfulness Application for Aggression in Schizophrenia
The study investigates whether a virtual reality-based mindfulness based intervention can reduce impulsive aggression in individuals with schizophrenia or schizoaffective disorder.
- Conditions
- Schizophrenia Disorder, Schizoaffecitve Disorder, Aggression
- Trial name
- NCT07434479
- Testing
- Mindfulness-Based Virtual Reality Intervention
- Where
- 2 sites in United States
- Volunteers
- 58 people
- Sponsor
- Manhattan Psychiatric Center
Acute Coronary Syndrome, Cardiovascular Diseases
Aggressive Smoking Cessation Trial (ASAP)
The ASAP Trial is a 5-year, multi-centre, randomized controlled trial that will assess the efficacy, safety, and tolerability of aggressive smoking cessation therapy among people at elevated cardiovascular risk.
- Trial name
- ASAP (NCT05257629)
- Testing
- Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling), Varenicline Plus Counseling
- Where
- 13 sites in Canada
- Volunteers
- 798 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
B-cell Non-Hodgkins Lymphoma (B-NHL)
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug[s]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs).
- Trial name
- ATHENA-1 (NCT05685173)
- Testing
- Odronextamab, REGN5837
- Where
- 20 sites in United States, France and 3 more
- Volunteers
- 107 people
- Sponsor
- Regeneron Pharmaceuticals
Meningioma
Search for Circulating Tumour Cells in the Blood and/or Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas: Proof-of-concept Study
The goal of the clinical trial is to assess the presence of circulating tumor cells (CTCs) in the blood and/or cerebrospinal fluid (CSF) of patients with aggressive recurrent meningiomas.
- Trial name
- BIOLIMEN-1 (NCT07398170)
- Testing
- Blood sampling, Lumbar puncture
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Montpellier
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL
This study aims to investigate a novel therapeutic strategy of integrated radiotherapy before autologous stem cell transplantation (ASCT) sequential chimeric antigen receptor T-cell(CAR-T) therapy for patients with…
- Trial name
- NCT07059741
- Testing
- integrated low-dose RT with reduced SEAM/TB conditioning before ASCT sequential CAR-T, integrated high-dose RT with reduced SEAM/TB conditioning before ASCT sequential CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Emotion Regulation Difficulties; Risky Behaviors (Substance Use, Risky Sexual Behavior, Self-harm, Aggression, Disordered Eating)
The Effects of the PsyPills App on Emotion Regulation and Risk Behaviors in Emerging Adults: A Randomized Clinical Trial
This study aims to investigate the effects of the PsyPills mobile application on improving emotion regulation and reducing risk behaviors among emerging adults.
- Trial name
- NCT07304830
- Testing
- PsyPills, MoodWheel
- Where
- Romania
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Babes-Bolyai University
Prostate Cancer
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation
- Trial name
- CONCORD (NCT07052578)
- Where
- 28 sites in Russia
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Intimate Partner Violence
Adapting the Manage Emotions to Reduce Aggression Therapy to Reduce Intimate Partner Violence and Promote Psychosocial Recovery in Veteran Couples (MERA-C)
This study will address a pressing unmet need for effective and accessible treatment for Veteran couples with intimate partner violence (IPV).
- Trial name
- MERA-C (NCT07749755)
- Testing
- Manage Emotions to Reduce Aggression- Couples, Manage Emotions to Reduce Aggression
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- VA Office of Research and Development
Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia)
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo pharmacokinetic profile, and preliminary efficacy…
- Conditions
- Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL), AML (Acute Myelogenous Leukemia), Myeloma Multiple, B-ALL
- Trial name
- CAR-T (NCT06911710)
- Testing
- CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University General Hospital
Problem Behavior, Aggression
Extensions of Resurgence as Choice
Although behavioral treatments for decreasing destructive behavior, such as differential reinforcement of alternative behavior (DRA), are effective in the clinic, problem behavior often returns when a caregiver does not give the…
- Conditions
- Problem Behavior, Aggression, Self-Injury
- Trial name
- NCT05537610
- Testing
- CDT, Control
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Diffuse Large B-Cell Lymphoma (DLBCL)
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
This study will test a new experimental study drug called REGN9220 with a Regeneron drug called odronextamab (both called "study drug") to see if it can help treat people with aggressive BCNHL that has either come back/gotten…
- Trial name
- NCT07887750
- Testing
- REGN9220, Odronextamab
- Volunteers
- 36 people
- Sponsor
- Regeneron Pharmaceuticals
Endometrial Cancer
An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation
Multicenter, observational, prospective study of molecular profiling in advanced and aggressive endometrial cancer patients and 1-st line treatment approaches in Russian Federation
- Trial name
- IREN (NCT07041606)
- Where
- 19 sites in Russia
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Resting Heart Rate, Blood Glucose Control
Assessing the Effects of Cool Roofs on Indoor Environments and Health in Tavua, Fiji
Ambient air temperatures in Fiji are increasing due to climate change. Solutions are needed to build heat resilience in communities and adapt.
- Conditions
- Resting Heart Rate, Blood Glucose Control, Depression, Heat-related Symptoms
- Trial name
- NCT07592117
- Testing
- Cool roof
- Where
- Fiji
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Aditi Bunker
Breast Cancer
Clinical and Biological Study of Early-onset Breast Cancer and the Influence of the Reproductive Cycle on the Aggressiveness of the Disease
The incidence of breast cancer is increasing, particularly among young women. Cancers in young women are associated with a poor prognosis. The causes remain poorly understood.
- Trial name
- ARTEMIS (NCT07601152)
- Testing
- No Intervention: Observational Cohort
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Institut Cancerologie de l'Ouest